Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | CDC25A | P30304 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | PGR | P06401 | 1/20 | 0.69 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.69 |
| ▸ | VDR | P11473 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.69 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.69 |
| ▸ | DRD3 | P35462 | 1/20 | 0.69 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10534045 | 0.91 | MEN1 (0.60) | MEN1KMT2AMAPTCDC25AALDH1A1 | |
| SCHEMBL10597997 | 0.87 | ADORA3 (0.76) | MEN1KMT2AMAPTCDC25AALDH1A1 | |
| SCHEMBL11681017 | 0.87 | ADORA3 (0.76) | MEN1KMT2AMAPTCDC25AALDH1A1 | |
| SCHEMBL27542722 | 0.87 | ADORA3 (0.76) | MEN1KMT2AMAPTCDC25AALDH1A1 | |
| SCHEMBL11681021 | 0.87 | ADORA3 (0.76) | MEN1KMT2AMAPTCDC25AALDH1A1 | |
| SCHEMBL7516578 | 0.86 | MEN1 (0.81) | MEN1KMT2AMAPTCDC25AALDH1A1 | |
| SCHEMBL11129087 | 0.86 | MEN1 (0.81) | MEN1KMT2AMAPTCDC25AALDH1A1 | |
| SCHEMBL7518602 | 0.83 | MEN1 (0.68) | MEN1KMT2AMAPTCDC25AALDH1A1 | |
| SCHEMBL7520299 | 0.83 | MEN1 (0.68) | MEN1KMT2AMAPTCDC25AALDH1A1 | |
| Cholecalciferol SCHEMBL23878716 | 0.81 | MEN1 (1.00) | MEN1KMT2AMAPTCDC25AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112156097-A | Use of vitamin D for preventing or reducing chemotherapy-induced alopecia | 博格有限责任公司 | 2021-01-01 | — | — | CN | claimed |
| WO-2017017677-A1 | COMBINATION TREATMENT FOR LIVER DISEASE | GALMED RESEARCH AND DEVELOPMENT LTD. (IL) | 2017-02-02 | — | — | WO | claimed |
| US-20100009943-A1 | 2-Methylene-(22E)-25-(1-Methylene-Hexyl)-26,27-Cyclo-22-Dehydro-19-Nor-Vitamin D Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2010-01-14 | — | — | US | claimed |
| EP-1874320-A1 | COMPOSITION OF FILM-FORMING SOLUTION TYPE, COMPRISING VITAMIN D OR A DERIVATIVE THEREOF AND A CORTICOSTEROID, AND USE THEREOF IN DERMATOLOGY | Galderma S.A. (CH) | 2008-01-09 | — | — | EP | claimed |
| EP-1796680-A2 | METHODS OF TREATING SYMPTOMS OF MULTIPLE SCLEROSIS USING VITAMIN D AND RELATED COMPOUNDS | Teva Pharmaceutical Industries Ltd (IL) | 2007-06-20 | — | — | EP | claimed |
| WO-2006111426-A1 | COMPOSITION OF FILM-FORMING SOLUTION TYPE, COMPRISING VITAMIN D OR A DERIVATIVE THEREOF AND A CORTICOSTEROID, AND USE THEREOF IN DERMATOLOGY | GALDERMA S.A. (CH) | 2006-10-26 | — | — | WO | claimed |
| CN-1837813-A | Method for determining vitamin D content in effervescent preparation | SHANDONG DYNE OCEANIC BIO PHAR (CN) | 2006-09-27 | — | — | CN | claimed |
| WO-2006032053-A2 | METHODS OF TREATING SYMPTOMS OF MULTIPLE SCLEROSIS USING VITAMIN D AND RELATED COMPOUNDS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-03-23 | — | — | WO | claimed |
| EP-1047671-A1 | METHOD OF PREPARATION OF CHOLECALCIFEROL DERIVATIVES AND NEW INTERMEDIATE COMPOUNDS | INSTYTUT FARMACEUTYCZNY (PL) | 2000-11-02 | — | — | EP | claimed |
| EP-0998931-A1 | REMEDIES FOR DRY EYE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2000-05-10 | — | — | EP | claimed |
| WO-1999036400-A1 | METHOD OF PREPARATION OF CHOLECALCIFEROL DERIVATIVES AND NEW INTERMEDIATE COMPOUNDS | INSTYTUT FARMACEUTYCZNY (PL) | 1999-07-22 | — | — | WO | claimed |
| EP-0588539-B1 | Stabilized pharmaceutical compositions containing derivatives of vitamins D2 and D3 | TEVA PHARMA (IL) | 1997-02-05 | — | — | EP | claimed |
| EP-0413828-B1 | SOLID PREPARATION OF ACTIVE VITAMIN D3 HAVING IMPROVED STABILITY | TEIJIN LTD (JP) | 1996-04-17 | — | — | EP | claimed |
| US-5158944-A | Dispersed in excipient readily soluble in organic solvent, and basic substance | TEIJIN LIMITED (JP) | 1992-10-27 | — | — | US | claimed |
| JP-54112847-A | — | — | None | — | — | JP | disclosed |
| JP-54112846-A | — | — | None | — | — | JP | disclosed |
| JP-61254558-A | — | — | None | — | — | JP | disclosed |
| US-4022891-A | Novel 1α,24-dihydroxycholecalciferol compositions, novel precursors thereof, and processes for preparing them | TEIJIN LIMITED (JA) | 1977-05-10 | — | — | US | disclosed |
| US-4022891-A | Novel 1α,24-dihydroxycholecalciferol compositions, novel precursors thereof, and processes for preparing them | TEIJIN LIMITED (JA) | 1977-05-10 | — | — | US | disclosed |
| JP-H00892098-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009943-A1 | 2-Methylene-(22E)-25-(1-Methylene-Hexyl)-26,27-Cyclo-22-Dehydro-19-Nor-Vitamin D Analogs | CYP27B1, CYP24A1, VDR | MEN1 1901/4885KMT2A 4776/4885MAPT 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.